The Relevance between Iodine Nutritional Status and BRAFV600E Mutation on Papillary Thyroid Cancer

Mapping Intimacies ◽

10.20944/preprints202110.0343.v1 ◽

2021 ◽

Author(s):

Yan-Yu Lin ◽

Yu-Shan Hsieh

Keyword(s):

Papillary Thyroid Carcinoma ◽

Thyroid Carcinoma ◽

Selection Criteria ◽

Group Analysis ◽

Urinary Iodine ◽

Iodine Concentration ◽

Iodine Intake ◽

Urinary Iodine Concentration ◽

Papillary Thyroid ◽

Brafv600e Mutation

Papillary thyroid carcinoma (PTC) accounts for approximately 85%-90% of all thyroid cancers. BRAFV600E mutation is a highly specific target for papillary thyroid carcinoma (PTC) and may have a reciprocal causative relationship with iodide-metabolizing genes. Here, we performed a review of studies published in the past 10 years to determine the relationship between iodine intake and BRAFV600E mutation in patients with PTC. We searched the MEDLINE, PubMed, and EMBASE databases for studies published from 2009 to 2019; seven partially matched the selection criteria and were suitable for review, and five passed all selection criteria. We divided the patients into three groups by iodine intake: low (urinary iodine concentration [UIC] &lt;100 μg/L), adequate (UIC 100–200 μg/L), and high iodine intake groups (UIC ≥200 μg/L). Between-group analysis revealed no significant differences in the odds ratio of the prevalence of BRAFV600E mutation between the high and adequate/low iodine intake groups and between the adequate and low iodine intake groups. To further analyzed the results of studies, they exhibited U-shaped curves in the relation of deficient and excessive dietary iodine intake in BRAFV600E mutation. The results might suggest that iodine intake slightly influences the prevalence of BRAFV600E mutation in patients with PTC despite the heterogeneity of studies. Further research should explore potential mechanisms underlying the associations between iodine intake and BRAF mutation in PTC. The systematic review was registered in PROSPERO (CRD42021279462).

Download Full-text

Urinary iodine is increased in papillary thyroid carcinoma but is not altered by regional population iodine intake status: a meta-analysis and implications

Endocrine Journal ◽

10.1507/endocrj.ej18-0532 ◽

2019 ◽

Vol 66 (6) ◽

pp. 497-514

Author(s):

Ann-Rong Yan ◽

Xiaojuan Zhang ◽

Hong Shen ◽

Xia Zhou ◽

Rui Li ◽

...

Keyword(s):

Papillary Thyroid Carcinoma ◽

Thyroid Carcinoma ◽

Meta Analysis ◽

Urinary Iodine ◽

Iodine Intake ◽

Papillary Thyroid ◽

Regional Population

Download Full-text

Aggressive Papillary Thyroid Carcinoma without Brafv600e Mutation

Acta Medica Anatolia ◽

10.15824/actamedica.48684 ◽

2014 ◽

Vol 2 (4) ◽

Author(s):

Emine Demirbaş ◽

Mehmet Aşık ◽

Semra Özdemir ◽

Hacer Şen ◽

Fahri Güneş ◽

...

Keyword(s):

Papillary Thyroid Carcinoma ◽

Thyroid Carcinoma ◽

Papillary Thyroid ◽

Brafv600e Mutation

Download Full-text

BRAFV600E MUTATION IN PAPILLARY THYROID CARCINOMA. CLINICAL AND METHODOLOGICAL ASPECTS

Problems in oncology ◽

10.37469/0507-3758-2019-65-1-16-26 ◽

2019 ◽

Vol 65 (1) ◽

pp. 16-26

Author(s):

Pavel Rumyantsev ◽

Petr Nikiforovich ◽

Andrey Poloznikov ◽

Andrey Abrosimov ◽

Vladimir Saenko ◽

...

Keyword(s):

Papillary Thyroid Carcinoma ◽

Thyroid Carcinoma ◽

Kinase Inhibitors ◽

Anaplastic Carcinoma ◽

Braf V600e ◽

Papillary Thyroid ◽

Brafv600e Mutation ◽

Wide Range ◽

Methodological Aspects

Mutation BRAFV600E is highly specific for papillary thyroid carcinoma. It’s detected in 40-70% of all papillary thyroid carcinoma cases. Moreover this mutation is noticed in anaplastic carcinoma in 40-50%.This fact gives a chance to select patients and provide targeted therapy with multi-kinase inhibitors in cases of unresectable anaplastic carcinoma. The influence of BRAF V600E mutation for response to radioactive iodine therapy requires more evidence-based research. Existing methods for determining the BRAFV600E mutation have different accuracy, availability and cost. Other methodological aspects are also associated with the sample preparation of biological material, the quality of reagents, and the cross-validation of research results. In this review, on the basis of our own experience and literature data, the indications for determining the mutation of the BRAFV600E gene in clinical practice are refined, and a comprehensive comparative analysis of modern research methods has been conducted. This review is focused on a wide range of specialists of different types: oncologists, endocrinologists, radiologists, pathologists, and biologists.

Download Full-text

The Reliability of Iodine Concentration in Diaper-Retrieved Infant Urine Using Urine Collection Pads, and in Their Mothers’ Breastmilk

Biomolecules ◽

10.3390/biom10020295 ◽

2020 ◽

Vol 10 (2) ◽

pp. 295

Author(s):

Kjersti Sletten Bakken ◽

Ingvild Oma ◽

Synne Groufh-Jacobsen ◽

Beate Stokke Solvik ◽

Lise Mette Mosand ◽

...

Keyword(s):

Intraclass Correlation ◽

Urinary Iodine ◽

Correlation Coefficients ◽

Iodine Concentration ◽

Cross Sectional Study ◽

Iodine Intake ◽

Public Healthcare ◽

Urinary Iodine Concentration ◽

Childbearing Age ◽

Cross Sectional

Mild to moderate iodine deficiency is common among women of childbearing age. Data on iodine status in infants are sparse, partly due to the challenges in collecting urine. Urinary iodine concentration (UIC) is considered a good marker for recent dietary iodine intake and status in populations. The aim of this study was to investigate the reliability of iodine concentration measured in two spot-samples from the same day of diaper-retrieved infant urine and in their mothers’ breastmilk. We collected urine and breastmilk from a sample of 27 infants and 25 mothers participating in a cross-sectional study at two public healthcare clinics in Norway. The reliability of iodine concentration was assessed by calculating the intraclass correlation coefficients (ICC) and the coefficient of variation (CV). The ICC for infants’ urine was 0.64 (95% confidence interval (CI) 0.36–0.82), while the ICC for breastmilk was 0.83 (95% CI 0.65–0.92) Similarly, the intraindividual CV for UIC was 0.25 and 0.14 for breastmilk iodine concentration (BIC). Compared to standard methods of collecting urine for measuring iodine concentration, the diaper-pad collection method does not substantially affect the reliability of the measurements.

Download Full-text

Iodine status of consumers of milk-alternative drinks v. cows’ milk: data from the UK National Diet and Nutrition Survey

British Journal Of Nutrition ◽

10.1017/s0007114520003876 ◽

2020 ◽

pp. 1-9

Author(s):

M. Dineva ◽

M. P. Rayman ◽

S. C. Bath

Keyword(s):

At Risk ◽

Iodine Deficiency ◽

Urinary Iodine ◽

Iodine Concentration ◽

Iodine Intake ◽

Urinary Iodine Concentration ◽

Nutrition Survey ◽

Iodine Status ◽

Adults And Children ◽

The Uk

Abstract Milk is the main source of iodine in the UK; however, the consumption and popularity of plant-based milk-alternative drinks are increasing. Consumers may be at risk of iodine deficiency as, unless fortified, milk alternatives have a low iodine concentration. We therefore aimed to compare the iodine intake and status of milk-alternative consumers with that of cows’ milk consumers. We used data from the UK National Diet and Nutrition Survey from years 7 to 9 (2014–2017; before a few manufacturers fortified their milk-alternative drinks with iodine). Data from 4-d food diaries were used to identify consumers of milk-alternative drinks and cows’ milk, along with the estimation of their iodine intake (µg/d) (available for n 3976 adults and children ≥1·5 years). Iodine status was based on urinary iodine concentration (UIC, µg/l) from spot-urine samples (available for n 2845 adults and children ≥4 years). Milk-alternative drinks were consumed by 4·6 % (n 185; n 88 consumed these drinks exclusively). Iodine intake was significantly lower in exclusive consumers of milk alternatives than cows’ milk consumers (94 v. 129 µg/d; P < 0·001). Exclusive consumers of milk alternatives also had a lower median UIC than cows’ milk consumers (79 v. 132 µg/l; P < 0·001) and were classified as iodine deficient by the WHO criterion (median UIC < 100 µg/l), whereas cows’ milk consumers were iodine sufficient. These data show that consumers of unfortified milk-alternative drinks are at risk of iodine deficiency. As a greater number of people consume milk-alternative drinks, it is important that these products are fortified appropriately to provide a similar iodine content to that of cows’ milk.

Download Full-text

The ratio of BRAFV600E alleles can be used to assess the biological behavior of papillary thyroid carcinoma

10.1101/2020.10.31.20223610 ◽

2020 ◽

Author(s):

Dingcun Luo ◽

Yeqin Ni ◽

Shirong Zhang ◽

Yanping Xun ◽

Pan Zhao ◽

...

Keyword(s):

Papillary Thyroid Carcinoma ◽

Thyroid Carcinoma ◽

Tumor Recurrence ◽

Recurrence Risk ◽

Tumor Stage ◽

Biological Behavior ◽

Clinicopathological Parameters ◽

Quantitative Detection ◽

Papillary Thyroid ◽

Brafv600e Mutation

ABSTRACTBackgroundThe BRAFV600E mutations is an important molecular event in the occurrence and development of papillary thyroid carcinoma (PTC). A qualitative detection of the BRAFV600E mutation is still insufficient to explain the biological behavior of PTC. Though quantitative detection of the BRAFV600E mutation can reflect certain characteristics of PTC, its clinical value is still controversial. We aimed to investigate the association between the ratio of BRAFV600E alleles and clinicopathological parameters in PTC patients.MethodsGenomic DNA was extracted from specimens obtained from 329 PTC patients undergoing thyroidectomy. The ratio of BRAFV600E alleles was determined by amplification refractory mutation system (ARMS) and droplet digital polymerase chain reaction (ddPCR). Inconsistent results were further verified by next-generation sequencing (NGS). The clinicopathologic features, clinical tumor stage, and tumor recurrence risk stratification of all patients were correlated with the ratio of BRAFV600E alleles.ResultsThe sensitivity of ddPCR was superior to that of ARMS and almost the same as that of NGS. In total, 275 of 329 patients had the BRAFV600E mutation as determined by ARMS, ddPCR and NGS. The ratio of BRAFV600E alleles ranged from 0.17%-48.0%, with a median ratio of 12.58%, and significantly correlated with tumor size (p<0.001), capsule or extrathyroidal invasion (p<0.001), the number or rate of lymph node metastases (p<0.001), tumor stage (p=0.006) and tumor recurrence risk (p<0.001) but not with sex, age or multifocality. The ratio of BRAFV600E alleles was much lower in PTC patients with Hashimoto’s thyroiditis than in those without (p<0.001).ConclusionsThe ratio of BRAFV600E alleles can reliably reflect the biological behavior of PTC, making it a molecular-based stratification index of recurrence risk. The quantitative detection of BRAFV600E has the potential to guide the clinical diagnosis and treatment of PTC.

Download Full-text